VERACYTE, INC. — Director's Dealing 2020

Mar 4, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERACYTE, INC. (VCYT)
CIK: 0001384101
Period of Report: 2020-03-03

Reporting Person: Kennedy Giulia C (Chief Scientific & Med Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-03	Common Stock	M	3750	$6.45	Acquired	102872	Direct
2020-03-03	Common Stock	M	1563	$5.43	Acquired	104435	Direct
2020-03-03	Common Stock	M	5313	$9.05	Acquired	109748	Direct
2020-03-03	Common Stock	M	4407	$5.98	Acquired	114155	Direct
2020-03-03	Common Stock	S	30542	$25.3489	Disposed	83613	Direct
2020-03-03	Common Stock	S	2339	$25.9051	Disposed	81274	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-03	Stock Option (right to buy)	$6.45	M	3750	Disposed	2026-02-28	Common Stock (3750.0)	Direct
2020-03-03	Stock Option (right to buy)	$5.43	M	1563	Disposed	2026-03-14	Common Stock (1563.0)	Direct
2020-03-03	Stock Option (right to buy)	$9.05	M	5313	Disposed	2027-03-02	Common Stock (5313.0)	Direct
2020-03-03	Stock Option (right to buy)	$5.98	M	4407	Disposed	2028-03-01	Common Stock (4407.0)	Direct

Footnotes

F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019.

F2: Represents weighted average sales price. Sale prices for the transactions range from $24.77 to $25.75. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

F3: Represents weighted average sales price. Sale prices for the transactions range from $25.78 to $26.05. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

F4: The option is fully vested.

F5: The option became exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

F6: The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

F7: The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.